Document Detail


Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
MedLine Citation:
PMID:  23483298     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: The primary objective of this study was to evaluate the dose-limiting toxicities (DLTs) and identify the maximum-tolerated dose (MTD) and recommended dose of nab-paclitaxel plus gemcitabine as a first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma (PDA). METHODS: Patients with previously untreated advanced PDA were treated with nab-paclitaxel followed by gemcitabine (1,000 mg/m(2)) administered intravenously for 30 min on days 1 and 8 and repeated every 21 days. RESULTS: Patients received nab-paclitaxel at the following dose levels: 80 mg/m(2) (n = 3), 100 mg/m(2) (n = 6), and 120 mg/m(2) (n = 12). The DLTs evaluated were elevated alanine aminotransferase and febrile neutropenia. However, there had no two out of three to six patients experienced DLTs, the MTD was not met. A total of 93 cycles were administered. The most common grade 3/4 toxicities were neutropenia (9.52 %), thrombocytopenia (4.76 %), and sensory neuropathy (4.76 %). For 12 patients receiving 120 mg/m(2), the overall response rate and disease control rate were 41.67 and 83.33 %, respectively, and the median progression-free survival and overall survival were 5.23 and 12.17 months, respectively. CONCLUSIONS: Treatment with albumin-bound nab-paclitaxel (120 mg/m(2)) plus gemcitabine has a favorable safety profile with an encouraging antitumor effect in Chinese patients.
Authors:
Dong-Sheng Zhang; De-Shen Wang; Zhi-Qiang Wang; Feng-Hua Wang; Hui-Yan Luo; Miao-Zhen Qiu; Feng Wang; Yu-Hong Li; Rui-Hua Xu
Related Documents :
24002508 - Phase i study of arn-509, a novel antiandrogen, in the treatment of castration-resistan...
22932428 - Effects of amphetamine on the human brain opioid system - a positron emission tomograph...
23689718 - Evaluation of pharmacokinetic interaction between pa-824 and midazolam in healthy adult...
24976448 - Pharmacokinetic interaction between rosuvastatin and metformin in healthy korean male v...
2583878 - Comparative pharmacokinetic and pharmacodynamic study of four different brands of propr...
9594408 - Apnoeic responses to pulmonary and systemic challenge of capsaicin in cats.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-3-13
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-3-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, 510060, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro analysis of femtosecond laser as an alternative to acid etching for achieving suitable bond...
Next Document:  Effects of dexmedetomidine, midazolam, and propofol on acetylcholine release in the rat cerebral cor...